NasdaqCM - Nasdaq Real Time Price USD
ENDRA Life Sciences Inc. (NDRA)
At close: November 15 at 4:00 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -62.3 | -78.75 | -387.8 | -311.85 |
| Low Estimate | -62.3 | -78.75 | -387.8 | -311.85 |
| High Estimate | -62.3 | -78.75 | -387.8 | -311.85 |
| Year Ago EPS | -297.5 | -455 | -2,765 | -387.8 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | 300k |
| Low Estimate | -- | -- | -- | 300k |
| High Estimate | -- | -- | -- | 300k |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | ? | ? | ? | ∞% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -630 | -472.5 | -122.5 | -62.3 |
| EPS Actual | -297.5 | -455 | -140 | -9.54 |
| Difference | 332.5 | 17.5 | -17.5 | 52.76 |
| Surprise % | 52.78% | 3.70% | -14.29% | 84.69% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -62.3 | -78.75 | -387.8 | -311.85 |
| 7 Days Ago | -70 | -70 | -402.5 | -297.5 |
| 30 Days Ago | -70 | -70 | -402.5 | -297.5 |
| 60 Days Ago | -70 | -70 | -402.5 | -297.5 |
| 90 Days Ago | -70 | -70 | -402.5 | -297.5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | 1 | -- | 1 |
| Down Last 30 Days | -- | 1 | -- | 1 |
Growth Estimates
| CURRENCY IN USD | NDRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 79.06% | -- | -- | 5.00% |
| Next Qtr. | 82.69% | -- | -- | 12.00% |
| Current Year | 85.97% | -- | -- | 2.10% |
| Next Year | 19.58% | -- | -- | 12.20% |
Upgrades & Downgrades
| Maintains | Ascendiant Capital: Buy to Buy | 6/7/2024 |
| Reiterates | HC Wainwright & Co.: Buy | 3/31/2023 |
Related Tickers
APDN Applied DNA Sciences, Inc.
0.1620
-6.79%
STIM Neuronetics, Inc.
0.7100
-10.13%
MYNZ Mainz Biomed N.V.
0.2387
-4.52%
TTOO T2 Biosystems, Inc.
0.4970
-4.42%
ISPC iSpecimen Inc.
4.2000
-3.45%
CHEK Check-Cap Ltd.
0.7745
-5.55%
PSNL Personalis, Inc.
3.8900
-9.53%
PRPH ProPhase Labs, Inc.
0.7500
-0.19%
ACRS Aclaris Therapeutics, Inc.
2.0500
-5.96%
BDSX Biodesix, Inc.
1.3450
-3.93%